These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 12629447

  • 1. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
    Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier JL.
    Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.
    Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF.
    Diabetes Care; 1999 Sep; 22(9):1543-8. PubMed ID: 10480523
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ellisras Longitudinal Study 2017: elevated serum levels of carboxymethyl-lysine, an advanced glycation end-product, are associated with higher odds of developing endothelial dysfunction in black South African patients with type 2 diabetes mellitus (ELS 29).
    Mogale MA, Mhlanga CM, Gololo SS, Adu A.
    Cardiovasc J Afr; 1999 Sep; 30(4):193-197. PubMed ID: 31469381
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function.
    Wagner Z, Wittmann I, Mazák I, Schinzel R, Heidland A, Kientsch-Engel R, Nagy J.
    Am J Kidney Dis; 2001 Oct; 38(4):785-91. PubMed ID: 11576882
    [Abstract] [Full Text] [Related]

  • 9. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.
    Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T.
    Mol Med; 1999 Jun; 5(6):393-405. PubMed ID: 10415164
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M.
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [Abstract] [Full Text] [Related]

  • 12. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema.
    Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel R, Stahl P.
    Diabetologia; 2004 Aug; 47(8):1376-9. PubMed ID: 15258735
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.
    Berg TJ, Clausen JT, Torjesen PA, Dahl-Jørgensen K, Bangstad HJ, Hanssen KF.
    Diabetes Care; 1998 Nov; 21(11):1997-2002. PubMed ID: 9802757
    [Abstract] [Full Text] [Related]

  • 15. Role of N-ε- carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus.
    Choudhuri S, Dutta D, Sen A, Chowdhury IH, Mitra B, Mondal LK, Saha A, Bhadhuri G, Bhattacharya B.
    Mol Vis; 2013 Nov; 19():100-13. PubMed ID: 23378723
    [Abstract] [Full Text] [Related]

  • 16. Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus.
    van Deutekom AW, Niessen HW, Schalkwijk CG, Heine RJ, Simsek S.
    Eur J Endocrinol; 2008 May; 158(5):655-60. PubMed ID: 18426823
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients.
    Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E.
    Diabetologia; 2000 Nov; 43(11):1385-8. PubMed ID: 11126407
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.